

Monoclonal antibodies against SARS-CoV-2: potential game-changer still underused

Ivan Gentile^{1,2}, Alberto Enrico Maraolo³, Antonio Riccardo Buonomo¹, Mariano Nobile¹, Prisco Piscitelli,^{2,4} Alessandro Miani⁵, Nicola Schiano Moriello¹

1. Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.
2. Staff UNESCO Chair on Health Education and Sustainable Development, University of Naples Federico II, 80131 Naples, Italy.
3. First Division of Infectious Diseases, Cotugno Hospital, AORN Dei Colli, 80131 Naples, Italy.
4. Euro Mediterranean Scientific Biomedical Institute, Bruxelles, Belgium
5. Department of Environmental Science and Policy, University of Milan, Milan, Italy

Abstract

Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still in considerable numbers in many nations. Monoclonal antibodies are the ideal complement to vaccination in high-risk subjects who have been infected by SARS-CoV-2 and are at high risk of developing severe disease. Combining data provided by clinical trials and demographics of SARS-CoV-2 infections, this analysis tries to predict the benefits of an extensive use of monoclonal antibodies to reduce hospital admissions, deaths, and costs.

Introduction

Vaccination is the most effective way to protect from coronavirus disease 2019 (COVID-19), although it cannot represent the only way to cope with the ongoing pandemic (1–4). Italy is among the Western European countries most hit by the pandemic (5). Notwithstanding campaigns to provide extensive vaccine coverage and information about immunization, part of the population remains sceptical about the vaccination. Several factors, namely safety concerns, doubts about effectiveness, and the speed with which vaccines were developed contribute to vaccine hesitancy and it is unlikely that everyone will eventually agree to vaccination. Moreover, vaccination is less effective in immunosuppressed subjects such as transplanted patients and those with haematological malignancies. A significant proportion of these subjects will not develop an effective response and will be at risk of a severe disease.

Currently, the only effective therapy in patients with mild COVID-19 and who are risk of progression to severe disease is the early (ideally within 4-5 days from symptoms onset) administration of monoclonal antibodies against the spike protein. This therapy reduces both hospitalisations and deaths (6). In the attempt to provide real-life data on the current use of monoclonal antibodies against SARS-CoV-2 in western countries, we investigated the use of monoclonal antibodies in Italy, and estimated the impact of a more extensive use of this therapy on hospital admissions, deaths and costs.

Methods

We determined the number of new SARS-CoV-2 infections, hospitalisations, ICU admissions and death due to coronavirus disease in Italy between 2 April 2021 (the day Italy approved this therapy) and 5 August 2021. Data of new cases of SARS-CoV-2 infection are publicly available on the website of the Italian Ministry of Health (7). Using WebPlotDigitizer software, we extracted all other data from the graphs on the web page of the Italian National Institute of Nuclear Physics that were provided by Italian National Institute of Health (8). We assumed three scenarios of monoclonal antibody use in people over 70 years of age (rates of use of 50%, 70% or 90%), and estimated their respective consequences on hospital admissions, deaths and costs based on data reported in the REGEN-COV trial (NCT04425629) (6) because complete data were not available for the other approved monoclonal antibodies (i.e. Bamlanivimab plus Etesevimab and Sotrovimab) (9,10). We also estimated the potential economic benefit related to the use of monoclonal antibodies. The price of a monoclonal antibody was estimated at \$1,250 per treatment (11). The cost per hospitalisation was estimated as follows: without ICU \$16,924, with ICU \$57,934 (12). We assumed a ratio between hospitalisation without ICU and with ICU of 9:1, as seen in the target population in the study period, therefore the mean hospitalization cost was set at \$ 21,025.

Results and discussion

As shown in Table 1, 777,502 cases of SARS-CoV-2 infection were recorded during the study period. The incidence fluctuated from a high of 110,594 cases per week to a low of 5,099 cases per week. A total of 70,022 people were over the age of 70 years. There were 57,740 hospital admissions, of which 21,503 in people over 70 years of age. A total of 18,422 deaths were recorded, 9,963 of which among people over the age of 70.

In Italy monoclonal antibodies use is approved for patients with SARS-CoV-2 infection and with at least one risk factor for progression towards a severe disease. Age over 65 years is one of these factors. In the period considered, monoclonal antibodies were prescribed for 6,322 patients. It is not known how many monoclonal antibodies were prescribed in patients over 70. However, even

assuming that all 6,322 treatments were administered in patients in this age group, this figure represents 9.02% of all patients over 70.

Projecting a reduction in hospital admissions and deaths based on the data available (6), we estimate that, during the study period, hospital admissions and deaths would have declined by 13,798 and 6,313 respectively considering a rate of utilization of 90% as shown in Table 2. Complete projections are reported in Table 2.

Regarding costs, the expenditure for the acquisition of monoclonal antibodies is counterbalanced by the saving of hospital admissions as a consequence we estimate a total savings of \$211,338 million dollars in case of 90% use (see Table 3).

We acknowledge that this study presents several limitations; first of all, we projected the efficacy of monoclonal antibodies estimating a similar effectiveness in real-life compared to that from clinical trials. For example, the population considered in the present study was significantly different from that one enrolled in the trials at least in terms of median age; moreover, the estimate of the use of monoclonal antibodies is rough because it does not consider other categories in which monoclonal antibodies are indicated (e.g., subjects with immunodeficiency, diabetes, obese, etc.)

Conclusion

Use of monoclonal antibodies for SARS-CoV-2 infection between April and August 2021 in Italy has been very low. Even looking at the most prudential estimates, a more extensive use of these therapies could have prevented a high number of hospitalisations and deaths among patients over 70, together with a positive impact on COVID-19 related costs. These data should prompt authorities to create a higher interaction between general practitioners and facilities for monoclonal antibodies infusion, in order to refer patients at high-risk of deterioration as soon as possible.

Table 1. Data obtained in the period of interest.

	Total	Patients over 70 years (rate)
NEW SARS-COV-2 INFECTIONS	777,502	70,022 (9%)
HOSPITAL ADMISSIONS	57,440	21,503 (37.4%)
DEATHS	18,422	9,963 (54%)
MONOCLONAL ANTIBODIES ADMINISTRED	6,322	n.a.

Table 2. Projected hospital admissions and deaths in subjects above 70 years of age who received monoclonal antibodies.

	50% M.A. USE	70% M.A. USE	90% M.A. USE
HOSPITAL ADMISSIONS	13,837 (15,944 – 12,590)	10,771 (13,721 – 9,025)	7,705 (11,498 – 5,460)
REDUCTIONS	7,666 (5,559 – 8,913)	10,732 (7,782 – 12,478)	13,798 (10,005 – 16,043)
REDUCTIONS (%)	35.7% (25.9% - 41.5%)	49.9% (36.2% - 58.0%)	64.2% (46.5% - 74.6%)
DEATHS	6,456 (8,389 – 5,624)	5,053 (7,759 – 3,889)	3,650 (7,130 – 2,153)
REDUCTIONS	3,507 (1,574 – 4,339)	4,910 (2,204 – 6,074)	6,313 (2,883 – 7,810)
REDUCTIONS (%)	35.2% (15.8% - 43,6%)	49.3% (22.1% - 61.0%)	63.4% (28.4% - 78.4%)

M.A.; monoclonal antibodies; in parenthesis data with 95% C.I.

Table 3: Economic implications of extensive monoclonal prescription in patients over the age of 70.

PERCENTAGE OF M.A. USE	50%	70%	90%
NUMBER OF A.M. ADMINISTERED	35,011	49,015	63,020
COST OF M.A. (\$)	43,763,750	61,269,250	78,774,750
SAVING FOR H.A. REDUCTION (\$)	161,173,855	225,643,397	290,112,939
NET SAVING (\$)	117,410,105	164,374,147	211,338,189

H.A.: Hospital Admissions; M.A. monoclonal antibodies

References

1. Sadoff J, Gars M Le, Shukarev G, Heerwegh D, Truyers C, Groot AM de, et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. <https://doi.org/10.1056/NEJMoa2034201>. 2021 Jan 13;384(19):1824–35.
2. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020 Aug;396(10249):467–78.
3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2020 Dec;NEJMoa2035389.
4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <https://doi.org/10.1056/NEJMoa2034577>. 2020 Dec;383(27):2603–15.
5. Armocida B, Formenti B, Ussai S, Palestra F, Missoni E. The Italian health system and the COVID-19 challenge. *Lancet Public Heal*. 2020 May 1;5(5):e253.
6. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients. *medRxiv*. 2021 Jun 6;2021.05.19.21257469.
7. Covid-19 - Situazione in Italia [Internet]. [cited 2021 Sep 5]. Available from: <https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?area=nuovoCoronavirus&id=5351&lingua=italiano&menu=vuoto>
8. CovidStat INFN - Dati dell'ISS [Internet]. [cited 2021 Sep 5]. Available from: <https://covid19.infn.it/iss/>
9. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. <https://doi.org/10.1056/NEJMoa2102685>. 2021 Jul;
10. Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci DR, et al. Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. *medRxiv*. 2021 May 28;2021.05.27.21257096.
11. US demand for COVID-19 antibody treatments rising fast - PMLiVE [Internet]. [cited 2021 Sep 6]. Available from: https://www.pmlive.com/pharma_news/us_demand_for_covid-19_antibody_treatments_rising_fast_1376021
12. Kohli, Maschio, Becker, Weinstein. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. *Vaccine*. 2021 Feb 12;39(7):1157–64.